Psilocybe cubensis

# Research Output: Psilocybe cubensis

---

## Botanical Identity

**Accepted binomial:** *Psilocybe cubensis* (Earle) Singer  
**Family:** Hymenogastraceae (previously placed in Strophariaceae; molecular phylogenetics has moved the genus)  
**Order:** Agaricales  
**Kingdom:** Fungi (not a plant — the brief designation as "plant" reflects Psychedex's use of "plant" as a catch-all for botanical/fungal substances)

**First description:** Franklin Sumner Earle, 1906, described the species from Cuba as *Stropharia cubensis* Earle. Rolf Singer transferred it to *Psilocybe* in 1949, establishing the current accepted binomial *Psilocybe cubensis* (Earle) Singer [Ref 34].

**Synonyms:** *Stropharia cubensis* Earle (basionym), *Stropharia cyanescens* Murrill, *Hypholoma caerulescens* Pat., *Hypholoma coerulescens*, *Naematoloma caerulescens*, *Nematoloma caerulescens* [Ref 34].

**Genus phylogenomics:** Bradshaw et al. (2024, PNAS) established via phylogenomic analysis of 2,983 single-copy gene families from 71 metagenomes (including 23 type specimens) that the stem lineage of *Psilocybe* arose approximately 67 million years ago and diversified ~56 mya. *P. cubensis* belongs to the core psilocybin-producing clade. The psilocybin biosynthetic gene cluster first arose within *Psilocybe*, with 4–5 possible horizontal gene transfers to other mushroom genera between 40 and 9 mya. Two distinct gene cluster orders correspond to a deep split within the genus, possibly representing two independent acquisitions [Ref 2].

**Distribution and cultivation status:** *Psilocybe cubensis* is widely distributed in tropical and subtropical regions, most prominently in Mexico, Central America, northern South America, the southern United States (especially Texas, Florida, Louisiana), Southeast Asia (Thailand, Vietnam, Cambodia), and Australia. It is a coprophilous species — growing naturally on the dung of large herbivores, particularly cattle and buffalo — in humid, warm environments. It is now one of the most widely cultivated psychedelic fungi globally, grown indoors using a variety of grain-based substrates (rye, brown rice flour/vermiculite, supplemented bulk substrates) [Ref 26]. In the brief, native range and cultivation status were absent; these findings fill that gap.

**Morphological features:** Cap (pileus) 1.5–8 cm broad; conical to broadly umbonate when young, becoming broadly convex to plane with age; color pale yellowish-brown to golden-brown, often fading to whitish at margin; surface viscid (sticky when moist). Stipe (stem) 4–15 cm long, 0.4–1.4 cm thick; whitish, sometimes staining blue. Gills adnate to adnexed, grayish when young, becoming deep purplish-brown to nearly black with age as spores mature. **Bluing reaction:** flesh and broken surfaces turn blue/blue-green on bruising, resulting from oxidation of psilocin — a useful field identification marker [Ref 16].

**Misidentification risks:** Potentially dangerous look-alike genera include:
- *Galerina marginata* and related species — contain amatoxins (α-amanitin) and can be fatal. Distinguished by rusty-brown spore print (vs. purplish-black for *Psilocybe*), non-bluing tissue, and ring with fine dark fibrils.
- *Pholiota* species — bitter taste, no bluing, rusty-brown spores.
- Toxic *Cortinarius* species in some geographic ranges.
Strauss et al. (2022) and the Flament et al. (2020) toxicology review both emphasize the serious risk of *Galerina* misidentification, especially in wild-harvested settings [Ref 16, 47].

**FLAG for generation agent:** Psilocybe cubensis is a fungus, not a botanical plant. The brief lists it as type "plant." This should be flagged: the article voice may need to distinguish "fungal substance" from true plant substances. No botanically authoritative taxonomic database (POWO, which covers plants) will include this species; mycological databases (Index Fungorum, MycoBank, GBIF) are the correct sources.

---

## Alkaloid / Cannabinoid Profile

**Primary active constituents:**

1. **Psilocybin** (4-phosphoryloxy-N,N-dimethyltryptamine; O-phosphoryl-4-hydroxy-DMT)
   - PubChem CID: 10624
   - Molecular formula: C₁₂H₁₇N₂O₄P; MW: 284.25 g/mol
   - InChIKey: QVDSEJDULKLHCG-UHFFFAOYSA-N
   - A prodrug; dephosphorylated in the body to psilocin [Ref 5]

2. **Psilocin** (4-hydroxy-N,N-dimethyltryptamine; 4-OH-DMT)
   - PubChem CID: 4980
   - Molecular formula: C₁₂H₁₆N₂O; MW: 204.27 g/mol
   - InChIKey: SPCIYGNTAMCTRO-UHFFFAOYSA-N
   - The pharmacologically active form; crosses the blood-brain barrier; 5-HT₂A agonist [Ref 6]

3. **Baeocystin** (4-phosphoryloxy-N-methyltryptamine)
   - PubChem CID: 161359
   - Molecular formula: C₁₁H₁₅N₂O₄P; MW: 270.22 g/mol
   - Minor alkaloid, N-demethylated homologue of psilocybin

4. **Norbaeocystin** (4-phosphoryloxytryptamine)
   - PubChem CID: 9795063
   - Molecular formula: C₁₀H₁₃N₂O₄P; MW: 256.19 g/mol
   - Trace alkaloid

5. **Aeruginascin** (4-phosphoryloxy-N,N,N-trimethyltryptammonium)
   - Trimethylated tryptamine quaternary ammonium compound
   - First reported in *Inocybe aeruginascens* but also found in some Psilocybe species; proposed to modulate the subjective experience toward a more "pleasant" character via 5-HT₃ receptor agonism [Ref 1]

**Quantified concentrations (UHPLC-MS/MS data):**

Gotvaldová et al. (2022, IJMS) performed the largest published systematic alkaloid quantification study to date, analyzing 226 fruiting bodies from 82 collections across 7 genera using UHPLC coupled with tandem mass spectrometry [Ref 1]. Key findings:
- *Psilocybe* species had the highest psilocybin/psilocin concentrations among all genera tested
- Tryptamine alkaloid concentrations were **extremely variable** both between species and between individual collections of the same species
- For *P. cubensis* specifically, typical dried weight ranges reported in the literature are approximately **0.37–1.30% psilocybin** and **0.14–0.42% psilocin** (combined tryptamine content generally in the range of 0.5–1.6% by dry weight), though outlier specimens exist [Refs 1, 26]

Kurzbaum et al. (2025, Journal of Fungi) reviewed genetic diversity and strain variability in *P. cubensis* specifically, documenting how both genetics and environmental cultivation conditions (substrate, temperature, humidity, light cycle) significantly affect alkaloid biosynthesis yield [Ref 26]. Commercially named cultivar "strains" (e.g., Golden Teacher, B+, Cubensis Ecuador, Penis Envy) are not formally taxonomically recognized but do exhibit measurable potency differences in community reports. The Penis Envy cultivar in particular is widely reported as higher-potency; however, peer-reviewed quantification comparing named cultivars across matched conditions is limited at time of writing. **FLAG:** Comparative cultivar potency data for named P. cubensis strains lacks robust published HPLC data; community reports dominate this area.

**β-Carboline MAO inhibitors (critical finding):**

Blei et al. (2019, Chemistry – A European Journal) demonstrated that magic mushrooms (including *Psilocybe* species) simultaneously produce a cocktail of β-carboline monoamine oxidase inhibitors — including harmane and norharman — as biosynthetic products of L-tryptophan metabolism [Ref 4]. Using MALDI-MS imaging, β-carbolines were shown to accumulate toward hyphal apices. As potent MAO-A inhibitors, these compounds:
1. Are neuroactive in their own right
2. Slow the oxidative degradation of psilocin, extending its plasma half-life
3. Create a pharmacological milieu distinct from pure synthetic psilocybin

This finding is critical context for: (a) the entourage effect hypothesis; (b) the MAOI drug interaction risk (see Safety section); and (c) interpretation of whole-mushroom clinical data vs. pure psilocybin studies.

**Whole-mushroom extract vs. synthetic psilocybin:**

Shahar et al. (2024, Molecular Psychiatry) compared psychedelic mushroom extract (PME) vs. chemically synthesized psilocybin (PSIL) in mice. Head-twitch response was similar over 20 minutes. However, PME showed significantly more potent and prolonged synaptic plasticity markers (GAP43, synaptophysin) in frontal cortex, hippocampus, and amygdala at 11 days post-treatment. Frontal cortex metabolomics showed a differential profile — purines (guanosine, hypoxanthine, inosine) showed a progressive decline from vehicle to PSIL to PME, suggesting a gradient of metabolic effect [Ref 14]. **FLAG:** This data is preclinical (mouse); clinical equivalence or superiority of whole-mushroom preparations over synthetic psilocybin has not been demonstrated in controlled human trials.

---

## History & Ethnobotany

**Pre-Columbian and indigenous Mesoamerican use:**

*Psilocybe cubensis* and related species have been used ceremonially by Mesoamerican indigenous peoples for at least 3,000–3,500 years, based on archaeological evidence including mushroom-shaped stone effigies ("mushroom stones") found in Guatemala and southern Mexico, dating from approximately 1000 BCE to 900 CE. Winkelman (2019) reviews prehistoric evidence for entheogen use, noting that human serotonergic systems show greater psychedelic responsiveness than non-human primates, suggesting an evolutionary role [Ref 19].

The Mazatec people of Oaxaca, Mexico are the best-documented users of psilocybin mushrooms, where they are known as *teonanácatl* (Nahuatl: "flesh of the gods") or *nti si tho* (Mazatec). Maria Sabina, a Mazatec *curandera*, was the pivotal figure who introduced Western researchers to the Velada ceremony (mushroom healing ritual) in 1955. Spiers et al. (2024) provide an annotated bibliography of 49 scholarly works on Indigenous psilocybin mushroom practices from anthropology, history, archaeology, ethnolinguistics, and ethnomycology [Ref 17].

**Western discovery:**

R. Gordon Wasson (vice president of J.P. Morgan & Co. and amateur mycologist) participated in a Mazatec Velada ceremony with Maria Sabina in 1955. His account, published in *Life* magazine on May 13, 1957 ("Seeking the Magic Mushroom"), was the first major Western public exposure to psilocybin mushrooms and catalyzed scientific interest [Ref 48]. Wasson and his wife Valentina published the more comprehensive *Mushrooms, Russia and History* (1957) [Ref 49].

Roger Heim (French mycologist) accompanied Wasson and collected mushroom specimens, subsequently collaborating with Albert Hofmann (discoverer of LSD) at Sandoz Laboratories, Basel. Hofmann and colleagues isolated and chemically characterized psilocybin and psilocin in 1958, naming them after the *Psilocybe* genus [Ref 50]. The first chemical syntheses of psilocybin and psilocin were also achieved at Sandoz in 1958–1959.

**Twentieth century research and prohibition:**

Research on psilocybin for psychological and psychiatric applications proceeded through the late 1950s and 1960s, including Timothy Leary's Harvard Psilocybin Project (1960–1963) — a controversial series of studies that contributed to political controversy around psychedelics. In 1970, the U.S. government classified psilocybin as Schedule I under the Controlled Substances Act, effectively halting research for several decades.

A 2004 UCLA pilot study in cancer patients with anxiety reignited scientific interest, followed by the landmark Griffiths et al. (2006) double-blind controlled study at Johns Hopkins establishing that psilocybin could reliably occasion mystical-type experiences in healthy volunteers [Ref 29]. This initiated the current era of clinical psilocybin research.

Guzman's monograph *The Genus Psilocybe* (1983) remains the definitive mycological taxonomy of the genus [Ref 50], describing approximately 144 species at publication.

**Regulatory timeline:**
- 1958: Psilocybin isolated by Hofmann at Sandoz
- 1970: CSA Schedule I classification in the United States
- 1971: UN Convention on Psychotropic Substances lists psilocybin/psilocin as Schedule I; mushrooms themselves not explicitly listed
- 2004: UCLA pilot study reignites clinical research
- 2006: Griffiths landmark study published [Ref 29]
- 2018–2019: FDA grants Breakthrough Therapy Designation to psilocybin for TRD (Compass Pathways) and MDD (Usona Institute)
- 2020: Oregon Measure 109 passes (supervised psilocybin services)
- 2022: Colorado Proposition 122 passes (personal decriminalization + regulated healing centers)
- 2023 (July): Australia TGA rescheduling takes effect; psilocybin Schedule 8, authorized psychiatrists only, TRD indication [Ref 33]
- 2025 (August): DEA forwards petition to reschedule psilocybin from Schedule I to Schedule II [Ref 32]

---

## Neuroscience & Mechanism

**Primary receptor targets:**

Psilocin (the active metabolite of psilocybin) acts primarily as a **partial agonist at 5-HT₂A serotonin receptors**, particularly in pyramidal neurons of the prefrontal cortex. This is the principal mechanism underlying psychedelic effects in both animals and humans [Refs 24, 12, 9]. Additional receptor interactions include:
- **5-HT₁A** agonism — contributes to long-term synaptic depression via enhanced GABAergic tone (Domi et al., 2026 demonstrated 5-HT₁A-mediated, 5-HT₂A-independent LTD in the prelimbic cortex) [see PMID 41577180]
- **5-HT₂C** agonism — contributes to mood regulation
- **TrkB** (BDNF receptor) interaction — recent evidence suggests psilocin activates TrkB independently of 5-HT₂A, potentially explaining sustained neuroplastic effects [Ref 24]
- **5-HT₂B** — Colognesi et al. (2026) demonstrated metabolic effects (weight reduction, liver steatosis reduction) in mice via hepatic 5-HT₂B antagonism at sub-psychedelic doses [PMID 41475502]

**CNS mechanism — network level:**

The REBUS (Relaxed Beliefs Under Psychedelics) model proposed by Carhart-Harris & Friston (2019) provides the current dominant theoretical framework: psilocin relaxes high-level cortical "priors" (top-down predictions), allowing greater influence of bottom-up sensory information, leading to increased entropy in brain signal and altered perception [Ref 12].

Siegel et al. (2024, *Nature*) tracked individual brain changes using longitudinal precision fMRI (18 MRI visits per participant). High-dose psilocybin (25mg) caused >3-fold greater functional connectivity disruption than methylphenidate. Effects were strongest in the **default mode network (DMN)**, and driven by desynchronization at both local and global scales. A **persistent decrease in hippocampal-DMN connectivity** lasted for 3 weeks post-session, hypothesized as a neuroanatomical correlate of psilocybin's pro-plasticity and therapeutic effects [Ref 27].

**Pharmacokinetics (oral administration of psilocybin, as dried mushroom or synthetic):**

Meshkat et al. (2025) systematic review of 14 PK studies summarizes [Ref 5]:
- Psilocybin rapidly dephosphorylated to psilocin by intestinal alkaline phosphatase and tissue phosphatases
- **Tmax for psilocin:** 1.8–4 hours (oral) — consistent with onset 30–60 min, peak effects 2–3 hours
- **Cmax:** 8.2 ± 2.8 ng/mL at doses of ~10–20 mg psilocybin [Ref 6]
- **Oral bioavailability:** 52.7 ± 20% [Ref 6]
- **Volume of distribution:** 277–1016 L (large; extensive tissue distribution)
- **Elimination half-life:** 1.5–4 hours for psilocin
- **Metabolic pathway:** Primarily CYP2D6 and CYP3A4; secondary monoamine oxidase A (MAO-A). Primary metabolites: 4-hydroxyindole-3-acetic acid (4-HIAA) and 4-hydroxytryptophol
- Note: β-carbolines endogenously produced in the mushroom inhibit MAO-A, potentially extending the effective half-life of psilocin from whole mushrooms relative to synthetic psilocybin [Ref 4]

**Intravenous pharmacokinetics (Hasler et al. 1997):**
- IV 1mg psilocybin: psilocin Cmax 12.9 ± 5.6 ng/mL at 1.9 ± 1.0 min (confirming rapid dephosphorylation in blood) [Ref 6]
- 4-HIAA not detected after 1 mg IV (insufficient for full oxidative metabolism)

**CYP enzyme involvement:**
- CYP2D6 poor metabolizers may have prolonged/intensified psilocin exposure
- CYP2D6 inhibitors (e.g., paroxetine, fluoxetine) may alter psilocin kinetics — though evidence is indirect from LSD PK data showing paroxetine increasing LSD exposure 1.4–1.5× [PMID 40022427]; a comparable mechanism is plausible for psilocin
- **FLAG:** Direct clinical CYP2D6 inhibition studies for psilocybin specifically are lacking; this is an important pharmacokinetic gap

---

## Effects & Dose by Preparation

**NOTE on dose conventions:** Clinical research uses synthetic psilocybin in mg or mg/70kg. Community use primarily uses dried whole mushrooms (grams). The relationship between the two is dose-range dependent and complicated by alkaloid variability in dried mushrooms.

**Approximate dose conversion (FLAG — not verified in a single published source; calculated from alkaloid range data):**
- Average P. cubensis: ~0.5–1.0% combined tryptamines (psilocybin + psilocin) by dry weight [Ref 1]
- Therefore 1 gram dried mushroom ≈ 5–10 mg psilocybin equivalent
- Typical "3.5g" dose ≈ 17–35 mg psilocybin equivalent
- **This conversion range is wide due to strain/batch variability; FLAG for generation agent: treat as illustrative range only**

**Preparation: Dried whole *Psilocybe cubensis* mushroom (oral ingestion — most common route)**

Dose tiers from community reports and available ethnopharmacological data:
- **Threshold:** 0.25–0.5 g dried mushroom (~1–5 mg psilocybin)
- **Common/moderate:** 1–3.5 g dried mushroom (~5–35 mg psilocybin equivalent)
- **High/strong:** 3.5–5 g (~17–50 mg psilocybin equivalent)
- **Heavy/heroic:** >5 g (>25–50 mg psilocybin equivalent)

**FLAG:** Threshold, common, and heavy dose values are derived from community ethnopharmacological consensus (harm reduction platforms) rather than a single controlled published study. They are directionally consistent with clinical trial doses but have NOT been directly verified against a peer-reviewed publication specific to dried P. cubensis mushrooms. The generation agent should treat these as community-derived estimates requiring flagging.

Clinical dose reference points:
- 10 mg synthetic psilocybin (Carhart-Harris et al. 2016): onset 30–60 min, peak 2–3h, subsided ≥6h [Ref 9]
- 25 mg: primary therapeutic dose in COMPASS Pathfinder trials [Ref 11]
- 30 mg/70kg Griffiths 2006 landmark study: reliable mystical experiences in healthy volunteers [Ref 29]
- 20–30 mg Davis et al. 2020 JAMA: rapid antidepressant effect from day 1 [Ref 10]

**Onset and duration:**
- Oral: onset 20–60 minutes; peak effects 2–3 hours; total duration 4–8 hours
- Effects duration from Carhart-Harris et al. 2016: "psychedelic effects typically became detectable 30–60 min after dosing, peaked 2–3h after dosing, and subsided to negligible levels at least 6h after dosing" [Ref 9]

**Preparation: Dried mushroom tea (oral infusion)**
- Common harm reduction practice; some users report slightly faster onset (~10–15 min earlier) and shorter overall duration due to more rapid gastrointestinal absorption
- Baeocystin and norbaeocystin are water-soluble and would be preserved in tea
- **FLAG:** No published controlled pharmacokinetic data specifically comparing tea vs. ingested dried mushroom in humans

**Preparation: Lemon tek (acidified pre-digestion)**
- Crushing dried mushrooms in acidic citrus juice; users report faster onset and shorter, more intense experience
- Proposed mechanism: citric acid partially hydrolyzes psilocybin to psilocin before ingestion, accelerating absorption
- **FLAG:** No peer-reviewed pharmacokinetic data confirms this mechanism in humans; based on in vitro chemistry and community reports

**Preparation: Psilocybin capsules / extracted/concentrated preparations**
- Increasingly available in harm reduction and semi-legal markets; potency highly variable
- **FLAG:** No systematic published data on pharmacokinetics of various extraction/concentration methods

**Subjective effects from controlled studies:**

Carhart-Harris et al. (2016, Lancet Psychiatry) documented at 25mg: "transient anxiety during drug onset (all patients), transient confusion or thought disorder (9/12), mild and transient nausea (4/12), and transient headache (4/12)" [Ref 9].

Griffiths et al. (2016, J Psychopharmacology) — high dose (22–30 mg/70kg): large decreases in clinician- and self-rated depression/anxiety, increases in quality of life, life meaning, optimism; 80%+ showed sustained improvement at 6 months; mystical-type experience on session day mediated outcomes [Ref 7].

**Dose–response characteristics:**
- Goodwin et al. (2022, NEJM): 25mg produced significantly greater MADRS reduction than 10mg (which was not significantly better than 1mg control), establishing a pronounced dose-response relationship in TRD [Ref 11]
- Higher doses produce more intense subjective experiences and more frequent mystical-type experiences

**Effect modifiers:**
- **Set and setting** (mindset and environment): Well-established from clinical literature as critical determinants of experience quality and safety; Haijen et al. (2018) confirmed empirically [PMID 30450045]
- **Prior experience:** Hallucinogen-naive vs. experienced users differ in preparation, expectations, and tolerance
- **Concurrent medications:** SSRIs may blunt subjective psychedelic effects (see Safety section)
- **Batch potency variability:** Individual mushroom alkaloid content varies by 2–4× even within the same cultivation batch [Ref 1]

---

## Safety & Toxicity

**General physiological safety profile:**

Psilocybin is widely characterized as having **low acute physiological toxicity**. Johnson, Richards & Griffiths (2008) summarize: "hallucinogens are relatively safe physiologically and are not considered drugs of dependence" [Ref 39]. No human fatalities from psilocybin toxicity alone have been documented in the peer-reviewed literature.

**LD50 and animal toxicology:**
- Rat oral LD50 for psilocybin: ~280 mg/kg (estimated from Lowe et al. 2021 [Ref 40])
- This places the therapeutic index extremely high relative to human doses (~0.1–0.5 mg/kg)
- No published human LD50 data

**Adverse effects from controlled clinical studies:**

Goodwin et al. (2022, NEJM) Phase 2 trial (233 participants): adverse events in 77% of all participants. Most common: **headache, nausea, dizziness**. Suicidal ideation or behavior or self-injury occurred in all dose groups (including 1mg control), consistent with underlying TRD population rather than drug effect [Ref 11].

Raison et al. (2023, JAMA): Single 25mg psilocybin — no serious treatment-emergent AEs; higher rate of overall and severe AEs vs. niacin placebo [Ref 28].

Carhart-Harris et al. (2016, Lancet Psychiatry): Adverse reactions limited to transient anxiety, confusion/thought disorder, mild nausea, transient headache — all resolved within session [Ref 9].

**Psychological risks:**

1. **Acute adverse reactions ("bad trip"):** The most common psychological risk. Characterized by overwhelming anxiety, fear, paranoia, panic, and/or dysphoric confusion. Risk is dose-dependent and context-dependent. Johnson et al. (2008) identified this as the primary risk, noting it could lead to potentially dangerous behavior such as leaving the study site [Ref 39].

2. **Persisting psychosis:** Rare. Hermle et al. (2008) reviewed hallucinogen-induced psychiatric disorders [PMID 18512184]. Johnson et al. (2008) note this as a less common but real risk, particularly in individuals with personal or family history of psychotic disorders [Ref 39].

3. **HPPD (Hallucinogen Persisting Perception Disorder):** Characterized by persistent visual disturbances (geometric hallucinations, halos, trails, static) after hallucinogen use ceases. Psilocybin and LSD are the most common precipitants [Ref 43]. Case reports confirm occurrence in adolescents [Ref 42] and adults. Prevalence not precisely established; Johnson et al. (2008) categorize it as rare with careful research protocols [Ref 39].

**Specific vulnerability populations:**
- **Personal or family history of psychosis, bipolar I, or schizophrenia:** Primary contraindication in all clinical protocols [Ref 39]
- **Active suicidal ideation:** Exclusion criterion in clinical trials [Ref 11]
- **Adolescents/pediatric:** Mori-Kreiner et al. (2025) HPPD case in 16-year-old; general developmental concerns; no clinical trials in minors
- **Cardiovascular disease:** 5-HT₂A/2B agonism produces sympathomimetic effects (transient increases in blood pressure, heart rate). Wsół (2023) notes insufficient data on safety in patients with established cardiovascular disease [Ref 21]; He et al. (2025) documented myocardial injury in *Psilocybe keralensis* poisoning [Ref 47]
- **Pregnancy:** No published human data; no published teratogenicity data; **FLAG: should be flagged for human review**
- **Hepatic impairment:** CYP2D6/CYP3A4 metabolism; impaired hepatic function could prolong psilocin exposure; **FLAG: no published data in hepatically impaired patients**

**Herb–drug interactions:**

1. **MAO inhibitors (MAOIs) + psilocybin mushrooms:** Hypertensive urgency/emergency has been documented in case reports (Rached et al., 2026 [Ref 23]). Mechanistic basis: β-carbolines in P. cubensis mushrooms inhibit MAO-A (which normally degrades psilocin and serotonin); combined with exogenous MAOIs, serotonin metabolism is severely inhibited, potentiating both serotonergic and sympathomimetic effects. **Evidence level: case reports (from Ref 23); mechanism well-understood.** Combination should be avoided.

2. **SSRIs:** Long-term SSRI use is associated with blunted subjective psychedelic effects, likely via 5-HT₂A receptor downregulation. Marwood et al. (2024, J Psychiatric Research) found that antidepressant discontinuation prior to psilocybin treatment did not significantly affect clinical outcomes in 233 TRD patients, challenging earlier reports of compromised efficacy [PMID 39427449]. Acute combination likely tolerable but may reduce effects; no serotonin syndrome cases from SSRI + psilocybin specifically documented.

3. **Lithium:** Psilocybin + lithium combination is potentially hazardous. The mechanism is proposed as: serotonergic amplification plus lithium's pro-convulsant effects at high levels. Case reports of seizures following lithium + psilocybin exist in the community literature; this was documented in the Johnson et al. (2008) safety guidelines [Ref 39]. **FLAG: peer-reviewed case reports specifically documenting lithium-psilocybin seizures were not retrieved in this search session; this specific interaction requires human editorial verification.**

4. **Cannabis:** Additive effects on anxiety and paranoia; no specific pharmacokinetic interaction. Commonly co-administered recreationally; may intensify subjective effects.

5. **Cardiovascular medications:** Indirect concern via sympathomimetic effects; no specific mechanism-based interactions documented in literature reviewed.

**Tolerance:**

Psilocybin/psilocin produces **rapid tachyphylaxis (functional tolerance)** via 5-HT₂A receptor downregulation. This is well-established from clinical and pharmacological literature, though specific published kinetic data for P. cubensis mushrooms in humans was not retrieved in this search. Cross-tolerance with LSD and other serotonergic psychedelics is established. In practice: administration on consecutive days produces substantially diminished effects; clinical protocols space sessions by 1–4 weeks. Johnson et al. (2008) note psilocybin is "not considered a drug of dependence" [Ref 39].

**FLAG:** Specific published studies quantifying tolerance development rate (e.g., receptor downregulation timecourse) in humans were not retrieved; this data gap should be noted.

**Dependence and withdrawal:**

Psilocybin produces **no physical dependence** and **no clinically recognized withdrawal syndrome** [Refs 39, 46]. The Diagnostic and Statistical Manual (DSM-5) does not list psilocybin/hallucinogen use disorder as a distinct disorder with withdrawal criteria. Some psychological habituation or craving in specific individuals is theoretically possible but not established in peer-reviewed literature. Meshkat et al. (2025) systematic review of psilocybin for SUDs found no addiction signals [Ref 35].

**Contaminant/adulterant risks:**

For commercially obtained or unverified "psilocybin mushrooms":
1. **Misidentification with toxic species** (Galerina, Cortinarius) is the primary physical safety risk in wild-harvested mushrooms [Ref 16]
2. **Adulteration** with synthetic substances (NBOMe compounds, research chemicals) in pressed pill or powder form claiming to be psilocybin; reagent testing (Ehrlich reagent, Hofmann reagent) can screen for psilocybin/psilocin vs. other indoles
3. **Potency variability**: Gotvaldová et al. (2022) document that tryptamine concentrations are "extremely variable, representing a problem for mushroom consumers due to the apparent risk of overdose" [Ref 1]
4. **Contamination of cultivated mushrooms**: Mold contamination (Trichoderma spp., cobweb mold) is common during cultivation; implies potential mycotoxin exposure, though specific data on mycotoxins in P. cubensis culture contamination is not available in reviewed literature

---

## Harm Reduction

**Published risk reduction strategies (from Johnson et al. 2008 [Ref 39]):**
- Screen for personal/family history of psychosis, bipolar I, schizophrenia (contraindication)
- Establish trust and rapport with session support before dosing
- Careful preparation and setting of intentions
- Safe physical environment (comfortable, private, quiet)
- Presence of at least one trusted sober support person ("sitter")
- Start with lower doses, especially for inexperienced users
- Do not combine with MAOIs, lithium, or cardiovascular medications without medical supervision

**Identification testing:**
- Ehrlich reagent (DMAB): purple/violet reaction indicates presence of indoles including psilocybin/psilocin; does NOT distinguish psilocybin from dangerous research chemical imposters with different indole backbones
- GC-MS or LC-MS/MS required for definitive quantification [Ref 30]
- DanceSafe and similar harm reduction organizations distribute reagent test kits

**Drug test considerations:**
- Standard workplace immunoassay urine drug screens (EMIT, fluorescence polarization immunoassay): **psilocin NOT reliably detected** — cross-reactivity of ~1.3% at 50 mg/L on amphetamine assay [Refs 30, 31]
- Confirmatory GC-MS or LC-MS/MS will detect psilocin in urine
- Psilocin is detectable in urine for approximately 24–72 hours after ingestion; exact detection window depends on dose and method sensitivity
- **FLAG:** Specific published detection window data for psilocin in urine across dose levels was not retrieved; this is a known gap

**Cessation and recovery:**
- No documented physiological withdrawal on cessation; no pharmacological treatment specifically indicated
- Psychological integration support (formal integration therapy) is increasingly common in clinical and harm reduction contexts following challenging experiences
- National resources: MAPS (Multidisciplinary Association for Psychedelic Studies), Zendo Project, Fireside Project (psychedelic crisis line)

---

## Legal Status

**International framework:**
- **UN Convention on Psychotropic Substances (1971):** Psilocybin and psilocin are listed as Schedule I substances. Signatory states are required to prohibit them except for medical and scientific research. **Importantly, psilocybin mushrooms themselves were NOT explicitly listed in the Convention** — largely due to pressure from the Mexican government, as the Convention text refers to pure compounds; this has created jurisdictional ambiguity worldwide [Ref 32].

**United States:**
- **Federal:** Psilocybin and psilocin are Schedule I under the Controlled Substances Act (CSA), 21 U.S.C. § 812. "No currently accepted medical use, high potential for abuse." Psilocybin-containing mushrooms are considered a Schedule I substance (containing a Schedule I compound) under federal law.
- **2025 development:** DEA forwarded a petition (August 2025) to reschedule psilocybin from Schedule I to Schedule II; outcome pending at time of research [Ref 32].
- **Oregon:** Measure 109 (passed November 2020) created Oregon Psilocybin Services — a licensed, supervised therapeutic framework. First service centers opened 2023. Psilocybin remains illegal for unregulated personal use.
- **Colorado:** Proposition 122 (Natural Medicine Health Act, passed November 2022) decriminalized personal use, possession, cultivation, and gifting of psilocybin for adults 21+. Regulated healing centers under development; additional natural medicines (DMT, ibogaine, mescaline) to be added by 2026. Denver, CO separately decriminalized psilocybin mushrooms in 2019.
- Other US cities with decriminalization: Oakland CA, Santa Cruz CA, Ann Arbor MI, Seattle WA, Detroit MI, Northampton MA, and others.
- **FLAG:** Legal landscape is rapidly evolving; state-level status requires up-to-date verification.

**Canada:**
- Psilocybin is a Schedule III controlled substance under the Controlled Drugs and Substances Act
- Health Canada authorized psilocybin access for palliative care and therapist training via Section 56 exemptions and the Special Access Program starting 2020–2022
- **FLAG:** Canadian regulatory specifics should be verified against Health Canada documentation

**United Kingdom:**
- Psilocybin is a Class A controlled substance under the Misuse of Drugs Act 1971, carrying the most serious penalties. The UK is a signatory to the 1971 UN Convention [Ref 32].

**Netherlands:**
- Psilocybin mushrooms ("paddos") were banned in 2008 following adverse media incidents
- Psilocybin-containing **truffles** (sclerotia of *P. tampanensis*, *P. mexicana*, and related species) remain legal and are sold openly in licensed "smart shops" as "magic truffles" or "philosopher's stones"
- **FLAG:** Truffle legality status should be verified against current Dutch law

**Germany:**
- Psilocybin is a controlled substance (Schedule I analogue under the Betäubungsmittelgesetz, BtMG)
- The Central Institute of Mental Health (CIMH, Mannheim) received approval for expanded access use in TRD patients through the German equivalent of a compassionate use pathway
- **FLAG:** German expanded access status should be verified against current BfArM records

**Australia:**
- Australia's Therapeutic Goods Administration (TGA) issued a final decision on 3 February 2023, rescheduling psilocybin from Schedule 9 (Prohibited Substance) to **Schedule 8 (Controlled Medicine)**, effective **1 July 2023** [Ref 33]
- Indication: Treatment-resistant depression (TRD) only
- Prescriber restriction: Must be a specialist psychiatrist with TGA Authorised Prescriber scheme approval
- Administration setting: Controlled medical environment with psychotherapy

**Jamaica:**
- Psilocybin mushrooms are **not scheduled** under Jamaican drug law. Psilocybin retreat centers operate legally; this has made Jamaica a prominent destination for psilocybin therapy tourism.

**Brazil:**
- Psilocybin is not explicitly listed as a controlled substance in Brazilian law; some legal ambiguity exists in practice.

---

## Clinical Trials

**Key completed and active trials:**

1. **NCT06898606** (Recruiting) — Phase 1: *Psilocybe cubensis* mushrooms with or without fluoxetine for refractory depression. Sponsor: Federal University of Latin American Integration (Brazil). **Notable:** This trial uses whole *Psilocybe cubensis* mushrooms rather than synthetic psilocybin — directly relevant to this article.

2. **NCT04718792** (Active, not recruiting) — Phase 2: Psilocybin for Alcohol Use Disorder. Sponsor: Anders Fink-Jensen, MD, DMSci (Copenhagen).

3. **NCT03300947** (Completed) — Phase 1: Psilocybin for OCD. Sponsor: University of Arizona.

4. **NCT02163707** (Completed) — Phase 1: UW Psilocybin Pharmacokinetics Study. Sponsor: University of Wisconsin, Madison.

5. **NCT05847686** (Completed) — Phase 1: Psilocybin-Assisted Therapy for Cancer-Related Anxiety in Metastatic Cancer. Sponsor: University of Washington.

**Major completed trials (from literature — not all on ClinicalTrials.gov with NCT IDs retrieved):**
- NCT00465595: Griffiths et al. 2016 cancer trial [Ref 7]
- NCT00957359: Ross et al. 2016 cancer trial [Ref 8]
- ISRCTN14426797: Carhart-Harris et al. 2016/2017 TRD [Refs 9, 13]
- NCT03181529: Davis et al. 2020 MDD JAMA [Ref 10]
- NCT03775200: Goodwin et al. 2022 NEJM (COMP360) [Ref 11]
- NCT03866174: Raison et al. 2023 JAMA (Usona) [Ref 28]

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief for this substance.

---

## Gaps & Flags

**Structural data gaps:**

1. **DOSE VALUES (FLAG):** Dose values for dried *Psilocybe cubensis* mushrooms (gram-based) are derived from community harm reduction consensus, not a single peer-reviewed clinical study. The conversion from dried mushroom grams to psilocybin mg is highly variable (0.5–1.6% alkaloid content range). Generation agent must present these with appropriate uncertainty framing and not as established clinical doses.

2. **WHOLE-MUSHROOM HUMAN PK DATA (FLAG):** No published human pharmacokinetic study specifically comparing dried whole P. cubensis mushroom ingestion vs. synthetic psilocybin oral administration was identified. All human PK studies use synthetic psilocybin. The β-carboline MAO inhibitor content of the mushroom (Blei et al. 2019) is expected to alter kinetics, but this has not been quantified in humans.

3. **NAMED CULTIVAR POTENCY (FLAG):** Comparative alkaloid quantification across named *P. cubensis* cultivars (Golden Teacher, B+, Penis Envy, etc.) lacks peer-reviewed HPLC data. Kurzbaum et al. 2025 review addresses this gap but primarily in the research context.

4. **TOLERANCE KINETICS (FLAG):** No peer-reviewed publication quantifying the specific rate of 5-HT₂A receptor downregulation and recovery timecourse in humans following psilocybin was retrieved. The statement that tolerance develops rapidly is clinically well-supported but the specific timeline is based on inference.

5. **LITHIUM INTERACTION (FLAG):** The lithium + psilocybin seizure risk is mentioned in safety guidelines (Johnson et al. 2008) but peer-reviewed case reports specifically documenting this interaction were not retrieved in this search session. Generation agent should present with appropriate evidence-level flagging.

6. **SSRI INTERACTION KINETICS (FLAG):** The degree to which SSRIs blunt psilocybin effects is documented in clinical observations but the direct CYP2D6 interaction between SSRIs and psilocin (as distinct from receptor-level effects) was not confirmed by a specific human PK study.

7. **PREGNANCY AND PEDIATRIC SAFETY (FLAG):** No published human safety data. Traditional-use accounts suggest historical use among adults only; no data on developmental effects.

8. **DETECTION WINDOW (FLAG):** Specific published psilocin urine detection windows across dose levels not retrieved. Standard immunoassay does NOT detect psilocin reliably; confirmatory GC-MS/LC-MS/MS required.

9. **CANADIAN LEGAL STATUS (FLAG):** Specific current details of Health Canada's Section 56 exemptions and Special Access Program for psilocybin require verification against current government sources.

10. **NETHERLANDS TRUFFLE LEGALITY (FLAG):** Current legal status of psilocybin truffles in the Netherlands requires verification against current Dutch Ministry of Health guidance.

11. **MISIDENTIFICATION RISK DATA:** While the risk of *Galerina* misidentification is qualitatively well-documented, no published studies specifically documenting P. cubensis misidentification-related poisoning incidence were identified. Case series exist in the broader Psilocybe poisoning literature.

12. **FUNGAL vs. PLANT DESIGNATION:** The database classifies P. cubensis as a "plant" substance. This is taxonomically incorrect (fungi are distinct from plants). The generation agent should consider appropriate language.

13. **β-CARBOLINE QUANTIFICATION IN P. CUBENSIS SPECIFICALLY:** Blei et al. (2019) demonstrated β-carbolines in magic mushrooms generally; the specific concentrations of harmane and norharman in *P. cubensis* fruiting bodies have not been quantified in a retrievable peer-reviewed study.